Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Abiomed Stock a Buy?

TheMotleyFool

0 0

Abiomed (NASDAQ: ABMD) struggled in 2019, but the stock has risen more than 62% so far this year. The question for most investors is how long that trend can continue for the medical device maker.

Abiomed's devices all have to do with the circulatory system, including the world's smallest heart pump, the Impella. Since the company acquired the Impella technology by buying German company Impella CardioSystems in 2005, Abiomed's revenue has risen every year.

In fiscal year 2020 (which ended on Mar. 31, 2020), the company reported revenue of $841 million, a 9% improvement over 2019. Its yearly operating income was $249.2 million, an improvement of 10.9% over 2019.

Source Fool.com

Like: 0

ABMD

Share